MGNX vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

MGNX

52.4
AI Score
VS
MGNX Wins

CBIO

45.5
AI Score

Investment Advisor Scores

MGNX

52score
Recommendation
HOLD

CBIO

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MGNX CBIO Winner
Revenue 20.77M 1.04M MGNX
Net Income -36.77M -48.12M MGNX
Net Margin -177.0% -4631.4% MGNX
Operating Income -33.44M -51.09M MGNX
ROE -173.5% -29.5% CBIO
ROA -16.9% -26.3% MGNX
Total Assets 217.87M 182.76M MGNX
Cash 66.52M 171.59M CBIO
Current Ratio 1.90 9.66 CBIO
Free Cash Flow -36.16M -28.56M CBIO

Relative Price Performance (Last 90 Days)

MGNX 1M: -18.9% · 3M: +22.0% CBIO 1M: -13.0% · 3M: -17.7%

Current Technical Phase

MGNX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 43

RSI (14): 43.4 · Price: $3.82

CBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 41

RSI (14): 41.2 · Price: $14.87

Fundamentals Snapshot

Metric MGNX CBIO
Market Cap
Forward P/E -2.7 -5.7
Trailing P/E
Revenue (TTM)
Revenue Growth 0.6% 0.0%
Gross Margin -0.2% 1.0%
Operating Margin -1.6% -14.3%
EPS -1.11 -0.14
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MGNX is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.